✓ Translated by DotMD AI Clinical Council Source: Research and practice in thrombosis and haemostasis • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #42824064 ↗

Phase III Randomized Trial: Denecimig (Mim8) prophylaxis over 52 weeks in adolescents and adults with hemophilia A: FRONTIER2 extension study (N = 281)

Original Paper Title: “Denecimig (Mim8) prophylaxis over 52 weeks in adolescents and adults with hemophilia A: FRONTIER2 extension study”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 281
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Denecimig maintained low ABRs over 52 weeks, was well tolerated, and improved patient-reported outcomes in adolescents and adults with HA with or without inhibitors.
  • Study Design & Sample: Phase III Randomized Trial published in Research and practice in thrombosis and haemostasis (N = 281 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Research and practice in thrombosis and haemostasis (2026), this phase iii randomized trial evaluating 281 human participants investigated: Denecimig (Mim8) is a fully human, activated factor VIII (FVIII) mimetic bispecific antibody in development for subcutaneous prophylaxis to prevent bleeding in persons with hemophilia A (HA). Key clinical takeaway: Denecimig maintained low ABRs over 52 weeks, was well tolerated, and improved patient-reported outcomes in adolescents and adults with HA with or without inhibitors.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Research and practice in thrombosis and haemostasis, 2026-08-15; N = 281; Rigor 87/100): Denecimig maintained low ABRs over 52 weeks, was well tolerated, and improved patient-reported outcomes in adolescents and adults with HA with or without inhibitors.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: hemophilia → Condition: blood-count-tests → Condition: anemia-folate-deficiency →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42824064: Phase III Randomized Trial: Denecimig (Mim8) prophylaxis over 52 weeks in adolescents and adults with hemophilia A: FRONTIER2 extension study (N = 281)

3 of 3 Free Questions Remaining